Sneddon Syndrome: A Rare Neurocutaneous Vascular Disease

Sneddon Syndrome is a rare, progressive disorder characterized by two hallmark features: cerebrovascular events and a distinct skin condition known as livedo racemosa. Although uncommon, this condition poses significant diagnostic and therapeutic challenges due to its complex presentation and the potential for serious complications.

---

Key Symptoms of Sneddon Syndrome

1. Livedo Racemosa
   This is a net-like, reddish-blue skin discoloration that most commonly appears on the arms and legs. Unlike the more common livedo reticularis, livedo racemosa is more persistent and widespread.

2. Cerebrovascular Events
   These include transient ischemic attacks (TIAs), strokes, and other neurologic symptoms such as hemiparesis, aphasia, or visual disturbances. These events may occur repeatedly and are a major source of morbidity in affected individuals.

3. Headaches and Dizziness
   Often occurring years before more severe symptoms, these early signs can be misleading and delay diagnosis.

4. Cognitive Impairment
   Patients may experience memory problems, personality changes, or progressive cognitive decline that can eventually lead to dementia.

5. Other Symptoms
   Nausea, aversion to certain foods, and even epileptic seizures have been reported in some cases. Additional complications may include hypertension, valvular heart disease, and increased rates of spontaneous miscarriages.

---

Risk Factors and Triggers

Several factors are thought to contribute to the development or exacerbation of Sneddon Syndrome:

• Genetic Predisposition: Familial clustering has been observed, and mutations in the CECR1 gene (coding for adenosine deaminase 2) have been identified in some patients.

• Autoimmune Disorders: Conditions such as lupus, antiphospholipid syndrome, and Behçet’s disease may be associated with Sneddon Syndrome.

• Lifestyle and Hormonal Factors: Smoking, oral contraceptive use, hyperlipidemia, and high blood pressure are considered potential risk factors or triggers.

In some cases, no clear underlying cause can be identified — such instances are considered idiopathic.

---

Pathogenesis: What Happens in the Body?

The syndrome results from a non-inflammatory arteriopathy affecting small to medium-sized arteries. Over time, smooth muscle cells within the blood vessels proliferate, narrowing the vessel lumen and eventually leading to vascular occlusion.

This compromised blood flow to the brain and skin explains the dual manifestation of livedo racemosa and neurological symptoms.

---

Diagnosis of Sneddon Syndrome

The diagnosis is based on a combination of clinical, laboratory, and imaging findings. Given its rarity and symptom overlap with other diseases, careful differential diagnosis is essential.

Diagnostic Tools and Procedures

• Clinical Examination: Identification of livedo racemosa and assessment of neurological symptoms.

• Blood Tests: Evaluation for autoimmune markers and clotting disorders, particularly antiphospholipid antibodies.

• Skin Biopsy: Can reveal characteristic vascular changes without significant inflammation.

• Imaging Studies:

  • MRI: Detects brain infarcts, white matter changes, microbleeds, and atrophy.

  • CT Scan: Useful but less sensitive than MRI.

  • Additional Tests: Echocardiography, vascular ultrasound, and advanced neurological evaluations may be warranted depending on the patient’s symptoms.

Differential Diagnosis

Other conditions that must be ruled out include:

• Autoimmune diseases

• Hypertension-related vascular damage

• Other vasculopathies

• Inflammatory arteriopathies (e.g., arteritis)

• Thrombophilia

If evidence of arteritis or a primary coagulation disorder is found, Sneddon Syndrome is unlikely to be the correct diagnosis.

---

Treatment Strategies

While there is no cure, the goal of treatment is to prevent further ischemic events and manage symptoms effectively.

Therapeutic Approaches

1. Anticoagulation
   For patients with antiphospholipid antibodies, long-term anticoagulation (e.g., warfarin) is standard to prevent thrombotic events.

2. Anti-thrombotic Therapy
   In patients without antiphospholipid antibodies, low-dose aspirin may be sufficient.

3. Vasodilators
   Drugs such as nifedipine can improve peripheral circulation and reduce livedo symptoms.

4. ACE Inhibitors
   These may help reduce endothelial proliferation and lower the risk of thrombosis.

5. Intravenous Immunoglobulins (IVIG)
   In selected cases with suspected autoimmune involvement, IVIG may offer benefit.

6. Supportive Pain Management
   Nonsteroidal anti-inflammatory drugs (NSAIDs) can be used for symptom relief.

7. Combination Therapy
   In more severe cases, a combination of anticoagulants, vasodilators, and anti-inflammatory medications may be used to enhance therapeutic effect.

---

Conclusion

Sneddon Syndrome is a complex, often underrecognized disease that lies at the intersection of neurology, dermatology, and vascular medicine. Early recognition of the skin and neurological signs — particularly the presence of livedo racemosa in conjunction with unexplained strokes or TIAs — is crucial for timely diagnosis and intervention.

Though rare, this condition requires a multidisciplinary approach for effective management. Ongoing research into the genetic and autoimmune mechanisms involved may pave the way for more targeted therapies in the future.

Reference:

Sneddon Syndrome: A Comprehensive Overview
https://www.sciencedirect.com/science/article/abs/pii/S1052305719302332#:~:text=Abstract.%20Sneddon%20syndrome%20(SS)%20is%20an%20episodic,violaceous%2C%20skin%20discoloration)%20and%20recurrent%20cerebrovascular%20events.

Sneddon Syndrome:  https://my.clevelandclinic.org/health/diseases/22957-sneddon-syndrome

© 2000-2025 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right. Library of Congress Card Number: LCN 00-192742